Novo Nordisk under pressure after Lilly's Foundayo cleared key EMA panel
FROM THE WIRE · FINANCE.YAHOO.COM
Eli Lilly's Foundayo just cleared a key European Medicines Agency panel for obesity and type 2 diabetes, putting direct pressure on Novo Nordisk (CPSE:NOVO B) and its oral Wegovy pill in the obesity treatment market. Novo Nordisk's share price has moved to DKK259.6, with the…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe EMA panel win for Foundayo increases GLP-1 competition for Novo Nordisk in the obesity market.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly's Foundayo cleared a European Medicines Agency panel for obesity and type 2 diabetes.
- 02Novo Nordisk shares are at DKK259.6, down 21.39% year to date.
- 03Investors weigh GLP-1 competition, U.S. pricing pressure and softer Wegovy pill momentum.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets